The transplant diagnostics market is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%. The growth of this market is mainly driven by increasing number of transplantation procedures, technological advancements in transplant diagnostics, increasing public and private funding for targeted research activities, and increasing burden on infectious diseases driving the growth of transplant diagnostics market.

Browse in-depth TOC on "Transplant Diagnostics Market"

153 – Tables

45 – Figures 

227 – Pages

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2531061

 

Key Market Players

 

Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux S.A. (France). Others are Immucor, Inc. (US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), and GenDx (Netherlands).

Growth Strategies Adopted:

An analysis of the developments in the transplant diagnostics market from 2016–2019 showed that product launches, expansions, agreements, partnerships, collaborations, and acquisitions were the most widely adopted growth strategies in the market.

Bio-Rad Laboratories, Inc. is the leading player in the global transplant diagnostics market. The company has a broad range of automated instruments for antibody screening and analysis, semi-automated systems for serological assays, standalone systems & reagents for molecular and non-molecular assay procedures, including transplant diagnostic products.

Hoffman-La Roche Ltd. is one of the major players in the market, as of 2019. The company has a broad product portfolio of transplant diagnostic products, including state-of-the-art instruments such as Rotor-Gene Q2plex System, QIAsymphony RGQ System, and EZ1 Advanced XL System and reagents such as GeneRead DNA Library Q Kit and RT2 qPCR Primer Assay for Human HLA-A.

QIAGEN has a strong geographic presence across the US, Canada, Brazil, Mexico, Germany, the UK, Switzerland, France, Japan, Australia, Canada, and Italy. QIAGEN collaborated with BioTeam (US), 10X Genomics (US), Seegene (South Korea), and Hitachi (Japan) to strengthen its R&D capabilities in the transplant diagnostics market.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=2531061

The molecular assays segment is expected to witness the highest growth during the forecast period.

The molecular assay technology segment is expected to register the highest CAGR during the forecast period. Factors such as its varied applications in patient profiling, rising public-private investments to support product development, and increasing clinical evidence of its efficacy are driving the growth of this segment.

North America accounted for the largest share of the transplant diagnostics market

North America accounted for the largest share of the transplant diagnostics market in 2019, followed by Europe. This can primarily be attributed to the continuous commercialization of innovative transplant diagnostic products coupled with ongoing advancements in the field of genomics and proteomics, recent discovery genetic biomarkers & their clinical role in immunoassay testing, and the increasing prevalence of chronic and communicable diseases.

Get 10% Customization on this Research Report @

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=25...